Microbot Medical (Nasdaq:MBOT) announced today that it received a new patent covering a modular robotic surgical system.
The USPTO granted the patent for a robot that includes a base and a plurality of tool-receiver units arranged as separate units and independently and interchangeably attachable to the base.
Hingham, Massachusetts–based Microbot said in a news release that it considers this patent significant as it potentially enables the adaptation of its Liberty surgical robotic system for a wider range of endovascular procedures. This would increase the total addressable market for the company. The patent also expands Microbot’s IP protection in the U.S. for the Liberty portfolio. It now includes 12 global patents, with 57 applications pending.
According to the company, the patent supports innovation and customization for different clinical needs. This enables Microbot to address other indications and increase its potential customer base.
Microbot designed the Liberty robot to democratize endovascular interventional procedures. The company says it’s the world’s first single-use, fully disposable robotic system for those procedures. The company submitted Liberty to the FDA in December 2024.
The company expects to launch its Liberty system during the third quarter of 2025. It remains actively engaged with the FDA ahead of its anticipated 510(k) approval. The company said this falls in line with the agency’s original scheduled review window and is not expected to impact its planned launch upon clearance. However, it marked a slight push back on the company’s original expectations for second-quarter clearance.
“We believe Liberty is one of the most advanced and distinctive robotic systems in the world, being the first fully disposable robotic system along with other unique features such as its modular capabilities. This patent recognizes yet another layer of our differentiation and could expand our reach to over 6 million annual endovascular procedures in the U.S. alone,” said Harel Gadot, Microbot chair, CEO & president. “Our near-term focus remains on the peripheral market and ensuring our commercial readiness plans in the U.S. are progressing as we await the FDA’s decision.”
